PHA-793887

Item number	Size	Delivery time	Price
TGM-T2113-2mg	2 mg	5 - 10 business days*	30.00€
TGM-T2113-5mg	5 mg	5 - 10 business days*	44.00€
TGM-T2113-1mL	1 ml	5 - 10 business days*	48.00€
TGM-T2113-10mg	10 mg	5 - 10 business days*	73.00€
TGM-T2113-25mg	25 mg	5 - 10 business days*	122.00€
TGM-T2113-50mg	50 mg	5 - 10 business days*	203.00€
TGM-T2113-100mg	100 mg	5 - 10 business days*	327.00€
TGM-T2113-500mg	500 mg	5 - 10 business days*	803.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic... more

Close menu

Product information "PHA-793887"

Description: PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors. Target: CDK, Apoptosis. Smiles: CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C. References: Brasca MG, et al. Bioorg Med Chem, 2010, 18(5), 1844-1853.

Keywords:	PHA 793887, PHA793887
Supplier:	TargetMol
Supplier-Nr:	T2113

Properties

Application:	CDK2, CDK5, CDK7 inhibitor
MW:	361.48 D
Formula:	C19H31N5O2

Database Information

CAS :	718630-59-2\| Matching products
KEGG ID :	K02206 \| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+20°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "PHA-793887"

Write a review